BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37759277)

  • 1. Malaria vaccine coverage estimation using age-eligible populations and service user denominators in Kenya.
    Moturi AK; Jalang'o R; Cherono A; Muchiri SK; Snow RW; Okiro EA
    Malar J; 2023 Sep; 22(1):287. PubMed ID: 37759277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RTS,S/AS01 malaria vaccine pilot implementation in western Kenya: a qualitative longitudinal study to understand immunisation barriers and optimise uptake.
    Hoyt J; Okello G; Bange T; Kariuki S; Jalloh MF; Webster J; Hill J
    BMC Public Health; 2023 Nov; 23(1):2283. PubMed ID: 37980467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility, safety, and impact of the RTS,S/AS01
    Asante KP; Mathanga DP; Milligan P; Akech S; Oduro A; Mwapasa V; Moore KA; Kwambai TK; Hamel MJ; Gyan T; Westercamp N; Kapito-Tembo A; Njuguna P; Ansong D; Kariuki S; Mvalo T; Snell P; Schellenberg D; Welega P; Otieno L; Chimala A; Afari EA; Bejon P; Maleta K; Agbenyega T; Snow RW; Zulu M; Chinkhumba J; Samuels AM;
    Lancet; 2024 Apr; 403(10437):1660-1670. PubMed ID: 38583454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.
    Asante KP; Ansong D; Kaali S; Adjei S; Lievens M; Nana Badu L; Agyapong Darko P; Boakye Yiadom Buabeng P; Boahen O; Maria Rettig T; Agutu C; Benard Ekow Harrison S; Ntiamoah Y; Adomako Anim J; Adeniji E; Agordo Dornudo A; Gvozdenovic E; Dosoo D; Sambian D; Owusu-Boateng H; Ato Wilson E; Prempeh F; Vandoolaeghe P; Schuerman L; Owusu-Agyei S; Agbenyega T; Ofori-Anyinam O
    Vaccine; 2020 Apr; 38(18):3411-3421. PubMed ID: 32192811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation.
    Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J
    BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.
    Otieno L; Oneko M; Otieno W; Abuodha J; Owino E; Odero C; Mendoza YG; Andagalu B; Awino N; Ivinson K; Heerwegh D; Otsyula N; Oziemkowska M; Usuf EA; Otieno A; Otieno K; Leboulleux D; Leach A; Oyieko J; Slutsker L; Lievens M; Cowden J; Lapierre D; Kariuki S; Ogutu B; Vekemans J; Hamel MJ
    Lancet Infect Dis; 2016 Oct; 16(10):1134-1144. PubMed ID: 27394191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study.
    Hogan AB; Winskill P; Ghani AC
    PLoS Med; 2020 Nov; 17(11):e1003377. PubMed ID: 33253211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
    Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
    PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of the RTS,S/AS01 malaria vaccine into the Essential Programme on Immunisation in western Kenya: a qualitative longitudinal study from the health system perspective.
    Hill J; Bange T; Hoyt J; Kariuki S; Jalloh MF; Webster J; Okello G
    Lancet Glob Health; 2024 Apr; 12(4):e672-e684. PubMed ID: 38430916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.
    Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR;
    Malar J; 2011 Aug; 10():224. PubMed ID: 21816029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi.
    Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I
    BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.
    Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC
    Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
    Vandoolaeghe P; Schuerman L
    Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of RTS,S/AS01
    Samuels AM; Ansong D; Kariuki SK; Adjei S; Bollaerts A; Ockenhouse C; Westercamp N; Lee CK; Schuerman L; Bii DK; Osei-Tutu L; Oneko M; Lievens M; Attobrah Sarfo MA; Atieno C; Morelle D; Bakari A; Sang T; Jongert E; Kotoh-Mortty MF; Otieno K; Roman F; Buabeng PBY; Ntiamoah Y; Ofori-Anyinam O; Agbenyega T;
    Lancet Infect Dis; 2022 Sep; 22(9):1329-1342. PubMed ID: 35753316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
    Baral R; Levin A; Odero C; Pecenka C; Tanko Bawa J; Antwi-Agyei KO; Amponsa-Achaino K; Chisema MN; Eddah Jalango R; Mkisi R; Gordon S; Morgan W; Muhib F
    Vaccine; 2023 Feb; 41(8):1496-1502. PubMed ID: 36710234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report.
    Merle CS;
    Malar J; 2023 Aug; 22(1):242. PubMed ID: 37612716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.
    RTS,S Clinical Trials Partnership
    Lancet; 2015 Jul; 386(9988):31-45. PubMed ID: 25913272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
    Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J
    Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
    Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
    PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.